The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Half of the participants took a semaglutide tablet daily and half took a placebo ... another type of diabetes drug with cardiovascular benefits. “There’s been a huge [open] question among ...

Although not approved for weight loss, this semaglutide tablet is often prescribed off label by healthcare ... Rybelsus is only available by prescription for select diabetic patients meeting ...

dulaglutide was once a week injection and now semaglutide which comes both in once a week injection and oral tablet form as well. These have been approved in India for use in diabetes patients.

Weight-loss jabs and those for diabetes ... that includes semaglutide, whose brand names include the jabs Wegovy and Ozempic, as well as Rybelus, which is taken as a tablet. Wegovy was approved ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Academics in the US analysed data from type 2 diabetes ... includes semaglutide, whose brand names include the jabs Wegovy and Ozempic, as well as Rybelus, which is taken as a tablet.

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...